| 1. |
- Campanella, A., et al.
(författare)
-
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments : A study by ERIC, the European Research Initiative on CLL
- 2024
-
Ingår i: American Journal of Hematology. - : John Wiley & Sons. - 0361-8609 .- 1096-8652. ; 99:4, s. 745-750
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
|
|
| 2. |
- Beth, Arnaud, et al.
(författare)
-
ROSINA ion zoo at Comet 67P
- 2020
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 642
-
Tidskriftsartikel (refereegranskat)abstract
- Context: The Rosetta spacecraft escorted Comet 67P/Churyumov-Gerasimenko for 2 yr along its journey through the Solar System between 3.8 and 1.24 au. Thanks to the high resolution mass spectrometer on board Rosetta, the detailed ion composition within a coma has been accurately assessed in situ for the very first time.Aims: Previous cometary missions, such as Giotto, did not have the instrumental capabilities to identify the exact nature of the plasma in a coma because the mass resolution of the spectrometers onboard was too low to separate ion species with similar masses. In contrast, the Double Focusing Mass Spectrometer (DFMS), part of the Rosetta Orbiter Spectrometer for Ion and Neutral Analysis on board Rosetta (ROSINA), with its high mass resolution mode, outperformed all of them, revealing the diversity of cometary ions.Methods: We calibrated and analysed the set of spectra acquired by DFMS in ion mode from October 2014 to April 2016. In particular, we focused on the range from 13–39 u q−1. The high mass resolution of DFMS allows for accurate identifications of ions with quasi-similar masses, separating 13C+ from CH+, for instance.Results: We confirm the presence in situ of predicted cations at comets, such as CHm+ (m = 1−4), HnO+ (n = 1−3), O+, Na+, and several ionised and protonated molecules. Prior to Rosetta, only a fraction of them had been confirmed from Earth-based observations. In addition, we report for the first time the unambiguous presence of a molecular dication in the gas envelope of a Solar System body, namely CO2++.
|
|
| 3. |
- Zubieta, Ezequiel, et al.
(författare)
-
First results of the glitching pulsar monitoring programme at the Argentine Institute of Radioastronomy
- 2023
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 521:3, s. 4504-4521
-
Tidskriftsartikel (refereegranskat)abstract
- We report here on the first results of a systematic monitoring of southern glitching pulsars at the Argentine Institute of Radioastronomy that started in the year 2019. We detected a major glitch in the Vela pulsar (PSR J0835 - 4510) and two small glitches in PSR J1048 - 5832. For each glitch, we present the measurement of glitch parameters by fitting timing residuals. We then make an individual pulse study of Vela in observations before and after the glitch. We selected 6 days of observations around the major glitch on 2021 July 22 and study their statistical properties with machine learning techniques. We use variational autoencoder (VAE) reconstruction of the pulses to separate them clearly from the noise. We perform a study with self-organizing map (SOM) clustering techniques to search for unusual behaviour of the clusters during the days around the glitch not finding notable qualitative changes. We have also detected and confirmed recent glitches in PSR J0742 - 2822 and PSR J1740 - 3015.
|
|
| 4. |
- Cadieux-Dion, M, et al.
(författare)
-
Variants in CHRNB2 and CHRNA4 Identified in Patients with Insular Epilepsy
- 2020
-
Ingår i: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. - : Cambridge University Press (CUP). - 0317-1671 .- 2057-0155. ; 47:6, s. 800-809
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose:Our purpose was to determine the role of CHRNA4 and CHRNB2 in insular epilepsy.Method:We identified two patients with drug-resistant predominantly sleep-related hypermotor seizures, one harboring a heterozygous missense variant (c.77C>T; p. Thr26Met) in the CHRNB2 gene and the other a heterozygous missense variant (c.1079G>A; p. Arg360Gln) in the CHRNA4 gene. The patients underwent electrophysiological and neuroimaging studies, and we performed functional characterization of the p. Thr26Met (c.77C>T) in the CHRNB2 gene.Results:We localized the epileptic foci to the left insula in the first case (now seizure-free following epilepsy surgery) and to both insulae in the second case. Based on tools predicting the possible impact of amino acid substitutions on the structure and function of proteins (sorting intolerant from tolerant and PolyPhen-2), variants identified in this report could be deleterious. Functional expression in human cell lines of α4β2 (wild-type), α4β2-Thr26Met (homozygote), and α4β2/β2-Thr26Met (heterozygote) nicotinic acetylcholine receptors revealed that the mutant subunit led to significantly higher whole-cell nicotinic currents. This feature was observed in both homo- and heterozygous conditions and was not accompanied by major alterations of the current reversal potential or the shape of the concentration-response relation.Conclusions:This study suggests that variants in CHRNB2 and CHRNA4, initially linked to autosomal dominant nocturnal frontal lobe epilepsy, are also found in patients with predominantly sleep-related insular epilepsy. Although the reported variants should be considered of unknown clinical significance for the moment, identification of additional similar cases and further functional studies could eventually strengthen this association.
|
|
| 5. |
|
|
